Ferden, Switzerland

Josef Werlen

This inventor holds 1 USPTO granted patent. Top assignee: Lonza Ag. Active years: 1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Josef Werlen. Retrieved from https://idiyas.com/inventor/josef-werlen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Josef Werlen

Introduction

Josef Werlen is a notable inventor based in Ferden, Switzerland. He has made significant contributions to the field of biochemistry, particularly in the metabolism of certain compounds. His work has implications for various health-related applications.

Latest Patents

Josef Werlen holds a patent for "Genes for butyrobetaine/crotonobetaine-l-carnitine metabolism and their." This patent reflects his innovative approach to understanding metabolic processes and their potential benefits.

Career Highlights

Werlen is currently employed at Lonza AG, a leading global supplier to the pharmaceutical, biotech, and specialty ingredients markets. His role at Lonza AG allows him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

One of his notable coworkers is Thomas Zimmermann. Together, they work on advancing the understanding of metabolic pathways and their applications in health and medicine.

Conclusion

Josef Werlen's contributions to the field of biochemistry through his patent and work at Lonza AG highlight his role as an innovative inventor. His research continues to pave the way for advancements in metabolic health.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…